公开(公告)号：EP1558084A2

公开(公告)日：2005-08-03

申请号：EP03776209.3

申请日：2003-09-30

申请人： UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  Yale University

发明人： BILLIAR, Timothy, R. ,  CHOI, Augustine, M.K. ,  MCCLOSKEY, Carol, A. ,  OTTERBEIN, Leo, E. ,  ZUCKERBRAUN, Brian, S.

IPC分类号： A01N59/04 ,  A61K33/00

CPC分类号： A61K45/06 ,  A61K33/00 ,  A61K2300/00

摘要： The present invention relates to methods and compositions of treating patients suffering from, or at risk for, hemorrhagic shock. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.

公开(公告)号：EP1553190A2

公开(公告)日：2005-07-13

申请号：EP04008958.3

申请日：1999-07-20

申请人： The University of Utah Research Foundation

发明人： Keating, Mark T. ,  Splawski, Igor

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C07H21/04

CPC分类号： C12Q1/6883 ,  A01K2217/05 ,  C07K14/705 ,  C12Q2600/156

摘要： The invention relates to the determination of the genomic structure of HERG which is a gene associated with long QT syndrome. The sequences of the 15 intron/exon junctions have been determined and this information is useful in devising primers for amplifying and sequencing across all of the exons of the gene. This is useful for determining the presence or absence of mutations which are known to cause long QT syndrome. Also disclosed are many new mutations in HERG which have been found to be associated with long QT syndrome.

摘要翻译： 本发明涉及作为与长QT综合征相关的基因的HERG的基因组结构的确定。 已经确定了15个内含子/外显子连接的序列，并且该信息可用于设计用于在基因的所有外显子上扩增和测序的引物。 这可用于确定已知引起长QT综合征的突变的存在或不存在。 还公开了已经发现与长QT综合征相关的HERG中的许多新突变。

公开(公告)号：EP1534731A1

公开(公告)日：2005-06-01

申请号：EP03788273.5

申请日：2003-08-18

申请人： Wyeth ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

发明人： BODINE, Peter, Van Nest ,  GAZIT, Dan

IPC分类号： C07H21/04 ,  C12N15/63 ,  C12N15/85 ,  C12N15/86 ,  C12Q1/68

CPC分类号： C12Q1/6897 ,  A61K48/00 ,  C07H21/04 ,  C07K14/51 ,  C12N15/85 ,  C12N2830/001 ,  C12N2830/008 ,  C12N2830/85

摘要： The invention relates to an isolated nucleic acid corresponding to BMP-2 regulatory region, or a fragment thereof comprising an estrogen responsive element, vector comprising the same and cells, which comprises said vector. In another embodiment, the invention provides methods of identifying an estrogen agonist, antagonist and a therapeutic agent in another embodiment the invention provides methods of treating conditions which are associated with estrogen insufficiency or with lack of response to external estrogen or agonists thereof.

公开(公告)号：EP1515753A1

公开(公告)日：2005-03-23

申请号：EP03742119.5

申请日：2003-06-20

申请人： UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  Beth Israel Deaconess Medical Center, Inc.

发明人： OTTERBEIN, Leo, E. ,  BACH, Fritz, H.

IPC分类号： A61K49/00

CPC分类号： A61K45/06 ,  A61K31/4025 ,  A61K31/409 ,  A61K33/00 ,  A61K33/26 ,  A61K2300/00

摘要： The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

公开(公告)号：EP1254186B1

公开(公告)日：2004-12-29

申请号：EP01910477.7

申请日：2001-02-08

申请人： ExxonMobil Chemical Patents Inc.

发明人： BURKHARDT, Terry, J. ,  WISER, Dawn, C. ,  LI, Robert, T. ,  STEHLING, Udo, M. ,  HAYGOOD, William, T., Jr. ,  RIX, Francis, C. ,  MEHTA, Aspy, K.

IPC分类号： C08F297/08

CPC分类号： B01J31/2295 ,  B01J21/08 ,  B01J31/143 ,  B01J31/1608 ,  B01J31/1616 ,  B01J2531/48 ,  C07F7/0818 ,  C07F7/0827 ,  C07F7/2212 ,  C07F7/30 ,  C07F17/00 ,  C08F4/65912 ,  C08F4/65916 ,  C08F10/00 ,  C08F10/06 ,  C08F110/06 ,  C08F210/06 ,  C08F210/16 ,  C08F297/08 ,  C08F297/083 ,  C08L23/10 ,  C08L23/12 ,  C08L23/142 ,  C08L23/16 ,  C08L2205/02 ,  C08L2308/00 ,  C08L2314/06 ,  Y02P20/52 ,  C08F4/65927 ,  C08F2/001 ,  C08L2666/04 ,  C08L2666/06 ,  C08F2500/03 ,  C08F2500/12 ,  C08F2500/17 ,  C08F2500/21 ,  C08F210/08

摘要： This invention relates to propylene impact copolymer compositions. In particular, these unique and improved compositions can be produced using conventional, commercial-scale processes.

公开(公告)号：EP1480658A2

公开(公告)日：2004-12-01

申请号：EP03743140.0

申请日：2003-02-13

申请人： Beth Israel Deaconess Medical Center, Inc. ,  University of Pittsburgh of the Commonwealth System of Higher Education

发明人： OTTERBEIN, Leo, E. ,  CHOI, Augustine, M., K. ,  BACH, Fritz, H. ,  ZUCKERBRAUN, Brian

IPC分类号： A61K33/00

CPC分类号： A61K33/00

摘要： The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

公开(公告)号：EP1463942A2

公开(公告)日：2004-10-06

申请号：EP02794380.2

申请日：2002-12-20

申请人： Immunex Corporation

发明人： VEDANTHAM, Ganesh ,  BROOKS, Clayton, A., III ,  REEDER, Joanne, M. ,  GOETZE, Andrew, M.

IPC分类号： G01N33/53

CPC分类号： C07K14/7151 ,  C07K1/16 ,  C07K1/22 ,  C07K14/70575 ,  C07K2319/00 ,  C07K2319/30

摘要： A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.

公开(公告)号：EP1432438A2

公开(公告)日：2004-06-30

申请号：EP02741848.2

申请日：2002-06-05

申请人： IMMUNEX CORPORATION

发明人： DOUGALL, William, C.

IPC分类号： A61K39/00 ,  A61K38/18

CPC分类号： C07K14/70578 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2878

摘要： Provided herein are methods of treating cancer by administering an effective amount of an agent that antagonizes the interaction between RANK and RANKL.

公开(公告)号：EP1432431A2

公开(公告)日：2004-06-30

申请号：EP02766319.4

申请日：2002-10-04

申请人： Genetics Institute, LLC

发明人： CARTER, Laura ,  WHITTERS, Matthew, J. ,  COLLINS, Mary ,  YOUNG, Deborah, A. ,  LARSEN, Glenn ,  DONALDSON, Debra, D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

IPC分类号： A61K38/00

CPC分类号： A61K31/519 ,  A61K31/42 ,  A61K31/453 ,  A61K38/1793 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2086 ,  A61K45/06 ,  C07K2319/30 ,  A61K2300/00

摘要： Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

公开(公告)号：EP1425415A2

公开(公告)日：2004-06-09

申请号：EP02757301.3

申请日：2002-08-20

申请人： Genaissance Pharmaceuticals, Inc.

发明人： SOTOS, John, G. ,  CURRAN, Mark, Edward ,  GUIDA, Marco ,  RIENHOFF, Hugh, Y., Jr.

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C12Q1/6883 ,  C12Q2600/156

摘要： The present invention provides methods and materials to identify genetic abnormalities that predispose an individual to ion-channel diseases. The invention provides four polymorphic sites in the KCNQ1 gene that cause reduced conductance of the associated potassium ion channel current and a variant form of the KCNE1 gene which causes decreased conductance though the channel. The variant form of KCNE1 also acts synergistically with variants of KCNQ1 to cause further decreased conductance than either variant alone. The invention further provides polymorphisms in ion channel genes showing a higher frequency in populations afflicted with ion channel diseases or within control groups. The detection of these polymorphic sites that produce the potassium ion channel protein variants in either heterozygous or homozygous form in a subject indicates that the subject has, or is susceptible to, ion channel diseases such as congenital or acquired cardiac arrhythmia, LQT syndrome, SIDS, epilepsy, or hearing loss.